Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Clinical trial NCT00656617 · COMPLETED

Trial details

NCT number: NCT00656617
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)

Start date: 2008-04-01
Primary completion: 2014-02-01
Enrollment: 106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.